DIFFUSE INTRINSIC PONTINE GLIOMA
Clinical trials for DIFFUSE INTRINSIC PONTINE GLIOMA explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE INTRINSIC PONTINE GLIOMA trials appear
Sign up with your email to follow new studies for DIFFUSE INTRINSIC PONTINE GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with tough cancers: personalized cell therapy trial launches
Disease control Recruiting nowThis early-stage trial tests a personalized cell therapy for children with recurrent neuroblastoma or newly diagnosed DIPG, two aggressive cancers. The treatment uses the child's own immune cells (dendritic cells and T cells) and stem cells, trained to attack their specific tumor…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: PHASE1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
New pill combo offers hope for kids with relapsed cancers
Disease control Recruiting nowThis study tests two oral drugs, eflornithine (DFMO) and AMXT 1501, in children and young adults up to age 26 with certain cancers that have come back or not responded to treatment. The cancers include neuroblastoma, brain tumors, and sarcomas. The goal is to find a safe dose and…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: PHASE1, PHASE2 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
Experimental drug TURALIO takes on tough childhood cancers in early trial
Disease control Recruiting nowThis early-phase study tests the drug TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or control leukemia. Participants take a daily capsule for up to 2 years, wit…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Targeted drug lorlatinib tested in kids with rare brain tumors
Disease control Recruiting nowThis early-phase study tests the drug lorlatinib in children and young adults (ages 1 to 21) with newly diagnosed high-grade glioma, a fast-growing brain tumor, that has a specific genetic change (ALK or ROS1 fusion). The goal is to see if the drug can shrink or control the tumor…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: EARLY_PHASE1 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for kids with deadly brain tumors: combination drug trial launches
Disease control Recruiting nowThis phase 2 trial is testing whether combining the drug ONC201 with other treatments (like paxalisib or a cancer-killing virus called DNX-2401) can help children and young adults with diffuse midline gliomas, a rare and aggressive brain cancer. The study enrolls 360 participants…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo therapy hopes to fight deadly childhood brain cancers
Disease control Recruiting nowThis trial tests a drug called selinexor combined with standard radiation in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) that has a specific genetic change (H3 K27M mutation). The study has two parts: first, fi…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for young brain cancer patients: targeted drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests whether adding the drug olutasidenib to standard chemotherapy (temozolomide) can help children and young adults with a specific type of brain cancer (IDH1-mutant high-grade glioma) live longer. About 60 participants will receive the combination as maintenance the…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: PHASE2 • Sponsor: Rigel Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for kids with tough cancers: drug combo trial launches
Disease control Recruiting nowThis study tests a new cancer drug, repotrectinib, combined with standard chemotherapy in children and young adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if the combination can shrink tumors. Researchers will also study how the b…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for kids with aggressive brain cancer: targeted drug combo trial launches
Disease control Recruiting nowThis study tests whether adding two different drug combinations after radiation can help children and young adults (up to age 21) with high-grade gliomas, including DIPG, live longer. One group receives ribociclib plus everolimus; another gets ribociclib plus temozolomide. The go…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for deadly brain tumors: Drug-Radiation combo trial opens
Disease control Recruiting nowThis study tests whether adding the drug VRT106 to standard radiation therapy can help control a rare, fast-growing brain tumor called diffuse midline glioma (including DIPG) in adults. About 10 participants aged 18 to 75 will receive the combination treatment. The main goal is t…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: PHASE2 • Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a vaccine help fight childhood brain cancer? new trial underway
Disease control Recruiting nowThis Phase 2 trial is testing a vaccine called PEP-CMV in 120 children and young adults with high-grade glioma, diffuse intrinsic pontine glioma (DIPG), or recurrent medulloblastoma. The vaccine targets a common virus (CMV) found in many brain tumors, aiming to boost the immune s…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Engineered t cells take on deadly brain cancers
Disease control Recruiting nowThis early-phase trial tests a new type of immune therapy for people with certain aggressive brain tumors, including DIPG and high-grade glioma. The treatment uses the patient's own T cells, which are modified in the lab to recognize a protein called GD2 on cancer cells and to pr…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Engineered immune cells take aim at childhood brain cancers
Disease control Recruiting nowThis early-phase study tests whether a new type of immunotherapy, called B7-H3 CAR T cells, can be safely given directly into the brain or spinal fluid of children and young adults with aggressive brain tumors like DIPG, DMG, or other recurrent central nervous system cancers. The…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental vaccine combo takes on childhood brain cancer
Disease control Recruiting nowThis early-phase trial is testing a new vaccine (rHSC-DIPGVax) made from pieces of tumor proteins, given together with two immunotherapy drugs (balstilimab and zalifrelimab), in children with DIPG or diffuse midline glioma. The goal is to see if the combination is safe and tolera…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: PHASE1 • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Targeted drug shows promise for rare childhood brain tumors
Disease control Recruiting nowThis early-phase trial is testing the drug larotrectinib in 15 children (up to age 21) with newly diagnosed high-grade glioma or DIPG that have a specific genetic change called NTRK fusion. The study aims to see if the drug can control the disease after two cycles, and how safe i…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: EARLY_PHASE1 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for kids with DIPG: major trial compares two treatments
Disease control Recruiting nowThis phase 3 trial tests whether the drug ONC201 works better than everolimus for children and adults with DIPG, a rare and aggressive brain tumor. About 433 participants will receive one of the two drugs, and can switch if their disease gets worse. The goal is to see which drug …
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Sound waves open brain barrier to attack deadly childhood tumors
Disease control Recruiting nowThis early study tests whether focused ultrasound can safely open the blood-brain barrier in children with progressive diffuse midline glioma (DMG), a rare and aggressive brain tumor. Ten children aged 4–21 will receive oral etoposide chemotherapy after ultrasound treatment to al…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: PHASE1 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Direct brain infusion trial offers new hope for kids with relapsed glioma
Disease control Recruiting nowThis study tests whether giving two drugs (cetuximab and bevacizumab) directly into the brain's blood vessels each month is safe and can shrink tumors or slow their growth. It includes children and young adults under 22 with certain types of brain tumors that have come back or no…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Engineered immune cells take on deadly brain tumors
Disease control Recruiting nowThis study tests a new treatment called 4sCAR-DLL3 CAR-T cells for people with DLL3-positive brain tumors, including glioblastoma and certain midline gliomas. The therapy uses a patient's own immune cells, modified to target and attack tumor cells. The trial will enroll 30 partic…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 26, 2026 17:50 UTC
-
Brain tumor DNA test could match kids to smarter treatments
Knowledge-focused Recruiting nowThis study uses genetic testing of brain tumors from children, adolescents, and young adults (ages 1 to 39) with newly diagnosed high-grade glioma, including DIPG. The goal is to identify specific genetic changes in each tumor and then see if patients can join a treatment trial t…
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Sponsor: Nationwide Children's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Worldwide effort to crack the code of deadly childhood brain tumors
Knowledge-focused Recruiting nowThis study creates a central registry and tissue bank for people with DIPG or DMG, rare and aggressive brain tumors. Researchers will collect medical information, scans, and tumor samples from up to 1,500 patients of any age. The goal is to understand the biology of these tumors …
Matched conditions: DIFFUSE INTRINSIC PONTINE GLIOMA
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC